Pharmacology - 07:01
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Career - Sep 20
WCER launches $1.5 million internship study of six Historically Black Colleges and Universities
WCER launches $1.5 million internship study of six Historically Black Colleges and Universities
science wire
« BACK
Pharmacology - Health - 31.07.2019
Pharmacology - Health - 30.07.2019
Health - Pharmacology - 26.07.2019
Pharmacology - Health - 26.07.2019
Pharmacology - Health - 26.07.2019
Pharmacology - 23.07.2019
Health - Pharmacology - 22.07.2019
Pharmacology - Health - 19.07.2019
Pharmacology - Business / Economics - 18.07.2019
Health - Pharmacology - 16.07.2019
Health - Pharmacology - 15.07.2019
Pharmacology - Health - 11.07.2019
Pharmacology - 11.07.2019
Pharmacology - Health - 09.07.2019
Health - Pharmacology - 02.07.2019
Pharmacology - Health - 02.07.2019
Pharmacology - Health - 01.07.2019
Pharmacology - Health - 01.07.2019
Pharmacology - Health - 01.07.2019
Health - Pharmacology - 28.06.2019
Pharmacology - Administration - 28.06.2019
Health - Pharmacology - 28.06.2019 
Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment. Breast cancer survivor Joy Jensen said such a test would give control back to those who felt helpless about their situation.
Pharmacology - Health - 26.06.2019
Health - Pharmacology - 24.06.2019
Pharmacology - 24.06.2019
Health - Pharmacology - 24.06.2019
Pharmacology - Health - 24.06.2019
Pharmacology - Health - 21.06.2019 
Protein hitch hiking into the cancer cell: the next generation of platinum drugs
The young spin-off "P4 Therapeutics" was awarded with the "Der Brutkasten Media Award" An interdisciplinary team of the University of Vienna and the Medical University of Vienna has developed a new platinum compound with great potential as anticancer drug.
Pharmacology - Health - 20.06.2019
Health - Pharmacology - 18.06.2019
Pharmacology - 17.06.2019
Health - Pharmacology - 17.06.2019
Health - Pharmacology - 14.06.2019
Health - Pharmacology - 14.06.2019
Pharmacology - Health - 12.06.2019
Health - Pharmacology - 12.06.2019
Pharmacology - 11.06.2019 
Cause of hardening of the arteries - and potential treatment - identified
Artery hardening happens to everyone as they age...but up until now we haven't known what controls this process and therefore how to treat it Melinda Duer New approach to drug discovery
Pharmacology - Health - 11.06.2019
Health - Pharmacology - 10.06.2019
Pharmacology - 10.06.2019
Business / Economics - Pharmacology - 07.06.2019
Health - Pharmacology - 06.06.2019
Health - Pharmacology - 06.06.2019
Health - Pharmacology - 04.06.2019
Pharmacology - Health - 04.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology - Health - 03.06.2019
Pharmacology
Results 51 - 100 of 1428.
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc
Roche and Spark Therapeutics, Inc.
Roche and Spark Therapeutics, Inc.
Yale and Mayo Clinic awarded FDA grant to study opioid prescribing and use
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients' experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI) , a joint effort between Yale, Mayo Clinic, and the FDA.
Yale University and Mayo Clinic have been awarded a grant for up to $5.3 million over two years by the U.S. Food and Drug Administration (FDA) to study patients' experiences with pain and use of opioids prescribed for acute pain. This project is part of the Center of Excellence in Regulatory Science and Innovation (CERSI) , a joint effort between Yale, Mayo Clinic, and the FDA.
Superbugs: A Pop-Up Science Shop (29th July - 11th August)
Ever wondered what micro-organisms are living on your skin? Drop into our interactive lab in the heart of Cardiff's busy shopping centre to find out, and you can even get pictures of them! Cardiff Un
Ever wondered what micro-organisms are living on your skin? Drop into our interactive lab in the heart of Cardiff's busy shopping centre to find out, and you can even get pictures of them! Cardiff Un
Novartis receives positive CHMP opinion for Lucentis treatment
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
Lucentis (ranibizumab), if approved in the EU for this indication, will be the first and only pharmacological therapy for ROP in these vulnerable infants Positive opinion is based on the landmark Pha
CHMP recommends EU approval of Roche’s Tecentriq in combination with chemotherapy
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
Decision based on results from first Phase III study to show a cancer immunotherapy-based combination significantly improved overall survival (OS) and progression-free survival (PFS) in over 20 years
FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from stand
Pioneering children’s cancer research role to speed up crucial clinical trials
University of Birmingham researchers are leading the way with a ground-breaking role to enable more children with the rare cancer neuroblastoma to access potentially life-saving clinical trials more quickly.
University of Birmingham researchers are leading the way with a ground-breaking role to enable more children with the rare cancer neuroblastoma to access potentially life-saving clinical trials more quickly.
Roche presents a broad range of data for Hemlibra demonstrating continued benefits for people with haemophilia A at the ISTH 2019 Congress
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
New analyses from phase III HAVEN studies support Hemlibra's sustained efficacy, safety and quality of life benefit in people with haemophilia A, with and without factor VIII inhibitors First data of
CHMP recommends EU approval of Tecentriq for people with breast cancer
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother
Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need First positive Phase III cancer immunother
Sussex Drug Discovery Centre appoints Professor Jeffrey Hill as new Director
Professor Jeffrey Hill has been appointed as the new Director of the Sussex Drug Discovery Centre ( SDDC ) within the School of Life Sciences.
Professor Jeffrey Hill has been appointed as the new Director of the Sussex Drug Discovery Centre ( SDDC ) within the School of Life Sciences.
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment. Breast cancer survivor Joy Jensen said such a test would give control back to those who felt helpless about their situation.
Long delays prescribing new antibiotics hinder market for needed drugs
U.S. hospitals wait over a year on average to begin prescribing newly developed antibiotics, a delay that might threaten the supply or discourage future development of needed drugs.
U.S. hospitals wait over a year on average to begin prescribing newly developed antibiotics, a delay that might threaten the supply or discourage future development of needed drugs.
New centre to fight drug-resistant bugs through improving use of antibiotics
A new Imperial centre will pioneer research to optimise how antimicrobial drugs are used to both improve patient care and preserve antibiotics.
A new Imperial centre will pioneer research to optimise how antimicrobial drugs are used to both improve patient care and preserve antibiotics.
The young spin-off "P4 Therapeutics" was awarded with the "Der Brutkasten Media Award" An interdisciplinary team of the University of Vienna and the Medical University of Vienna has developed a new platinum compound with great potential as anticancer drug.
MND Global Day - UQ experts available
University of Queensland experts are available to comment on various issues relating to MND Global Day on Friday 21 June.
University of Queensland experts are available to comment on various issues relating to MND Global Day on Friday 21 June.
Japan becomes the first country to approve Roche’s personalised medicine Rozlytrek
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Ph
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
For the first time efficacy and safety data from dedicated phase III trials are analyzed together in one abstract, backing Cosentyx as comprehensive treatment across multiple manifestations of psoria
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Data show switching to Hyrimoz (biosimilar adalimumab) from the reference medicine provides sustained efficacy with no new safety concerns in patients with moderate-to-severe rheumatoid arthritis A
Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib (ABL001)
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Results from two Phase II trials, ENESTfreedom and ENESTop, support and extend previous findings of long-term durability of molecular response after stopping Tasigna, reducing time on drug for many C
Novartis Cosentyx first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide 66
Cosentyx provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg Data at 2 years demonstrate over 50% of adults with active PsA achie
Artery hardening happens to everyone as they age...but up until now we haven't known what controls this process and therefore how to treat it Melinda Duer New approach to drug discovery
FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells Ninth indication with Breakthrough Therapy Designation in Roche's haematology portfolio to receive FDA approval Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy?
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium ( 177 Lu) Oxodot
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar + Mekinist
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine Results are from the largest dataset and longest follow-up of more than 500 patients with BRAF-mutated metastatic melanoma, a genetic mutation common for this aggressive skin cancer Additional Novartis melanoma research presented at ASCO includes effi
Pivotal phase III CLL14 results for Venclexta/Venclyxto in combination with Gazyva/Gazyvaro for chronic lymphocytic leukaemia presented at ASCO 2019 and published in the New England Journal of Medicine
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Venclexta/Venclyxto plus Gazyva/Gazyvaro showed improvements across multiple efficacy measures compared to Gazyva/Gazyvaro plus chlorambucil, including progression-free survival and deep remissions a
Drug increases survival for bladder cancer patients
There are no approved treatment options for patients with advanced bladder cancer after they've received standard chemotherapy and immune treatments, but the results of a phase II clinical trial led
There are no approved treatment options for patients with advanced bladder cancer after they've received standard chemotherapy and immune treatments, but the results of a phase II clinical trial led
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Roche data from 17 breast cancer abstracts presented at this year's meeting An overall survival improvement was observed with Tecentriq and nab-paclitaxel in PD-L1-positive metastatic triple-negative
Xolair (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate res
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)
Pharmacology - 07:01
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
Career - Sep 20
WCER launches $1.5 million internship study of six Historically Black Colleges and Universities
WCER launches $1.5 million internship study of six Historically Black Colleges and Universities